Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades-Reference-Cited by-同舟云学术

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Published:2017-11-01 Issue:11 Volume:3 Page:1503
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Esserman Laura J.¹,Yau Christina²,Thompson Carlie K.¹,van 't Veer Laura J.¹,Borowsky Alexander D.³,Hoadley Katherine A.⁴,Tobin Nicholas P.⁵,Nordenskjöld Bo⁶,Fornander Tommy⁵,Stål Olle⁶,Benz Christopher C.²,Lindström Linda S.⁷

Affiliation:

1. Helen Diller Family Comprehensive Cancer Center, University of California–San Francisco, San Francisco

2. Helen Diller Family Comprehensive Cancer Center, University of California–San Francisco, San Francisco2Buck Institute for Research on Aging, Novato, California

3. Center for Comparative Medicine, University of California–Davis, Davis

4. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill

5. Department of Oncology-Pathology, Karolinska Institutet and University Hospital, Stockholm, Sweden

6. Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden7Department of Oncology, Linköping University, Linköping, Sweden

7. Department of Biosciences and Nutrition, Karolinska Institutet and University Hospital, Stockholm, Sweden

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GATA3 and markers of epithelial-mesenchymal transition predict long-term benefit from tamoxifen in ER-positive breast cancer;npj Breast Cancer;2024-09-06

2. Breast Cancer With HER2 Immunohistochemical Score 2 and Average HER2 Signals/Cell 6 or More and HER2/CEP17 Ratio Less Than 2 ('ISH Group 3'): A Multi-Institutional Cohort Analysis Emphasizing Outcome and Molecular Subtype;Modern Pathology;2024-08

3. Hormone Deprivation–Free Survival—Inequities Persist in Research Priorities for Patients With Cancer;JAMA Oncology;2024-07-25

4. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial;Journal of Clinical Oncology;2024-07-24

5. Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays;Journal of Surgical Oncology;2024-06-24